March 13, 2018
Dear friends and colleagues,
You may have seen the recently announced news that SOLVO is joining the Citoxlab Group of companies. This acquisition marks the beginning in a new chapter of our company’s history. We are very pleased that the team at Citoxlab recognized with this investment the value our clients place on SOLVO’s unique leadership position within the transporter/ADME-Tox market, as well as our commitment to quality and customer service. Likewise, in Citoxlab we have found a company with the same passion for quality, driven by a true passion for the science that underpins our work. This acquisition will enable us to build upon these strong foundations and position us for further growth to help serve our clients’ needs in the ADME-Tox field.
As a result of the acquisition, our clients will not notice any change in the high level of service that you have come to expect from SOLVO. Similarly, there will be no immediate operational changes to the business, your account and study managers will remain the same, and all existing agreements will continue. In the long term, we look forward to harnessing the strength of this new partnership and bringing you more exciting developments in due course.
With best regards,
Berend Oosterhuis, COO, SOLVO Biotechnology
Joseph Zolnerciks, VP Business Development, SOLVO Biotechnology